FDA Removes the Black Box Warning From Hormone Therapy: What It Means For You

For more than two decades, every box of menopausal hormone therapy in the United States carried the FDA's most severe label — the black box warning. It told women, in stark bold print, that taking estrogen could cause heart attacks, strokes, breast cancer, and dementia.

On November 10, 2025, the FDA announced it would remove those warnings. On February 12, 2026, the first six products officially had their labels rewritten. This is the biggest shift in women's hormone care since the warning was first applied in 2002 — and if you have been told you "can't" or "shouldn't" consider hormone therapy, this changes the conversation entirely.

The black box warning was born from a single study: the Women's Health Initiative (WHI), published in 2002. Headlines that summer told millions of women that hormone therapy raised their risk of breast cancer, heart disease, and dementia. Prescriptions collapsed almost overnight.

The numbers tell the story:

• 1999: roughly 27% of postmenopausal women in the U.S. were on hormone therapy.
• 2020: that number had dropped to about 5%.

An entire generation of women was steered away from a treatment that could have eased their symptoms — and, as we now understand, may have offered long-term protection for their hearts, brains, and bones.

In the years since the WHI, researchers have re-examined the original data and uncovered serious problems. The study's average participant was 63 years old — well past the typical age a woman would start hormone therapy — and many had pre-existing cardiovascular risk factors. The risks reported in 2002 reflected an older, sicker population, not the women who actually need HRT in their late 40s and 50s.

Newer analyses tell a different story. When hormone therapy is started within 10 years of the onset of menopause, research has linked it to:

• Clinical Note: Up to a 50% reduction in heart attack risk.
• Clinical Note: A 64% reduction in cognitive decline.
• Clinical Note: A 35% lower risk of Alzheimer's disease.

This is the data that pushed the FDA to act. After an expert panel in July 2025 testified that the original risks had been overstated, the agency moved to update the labels.

The FDA removed boxed-warning language about three risks:

• Clinical Note: Cardiovascular disease (heart attack and stroke).
• Clinical Note: Breast cancer.
• Clinical Note: Probable dementia.

One warning does remain: the boxed warning for endometrial cancer on systemic estrogen-only products. This is not new science — it is why women with a uterus are prescribed progesterone alongside their estrogen. That protection has not changed.

The FDA approved updated labels on six menopausal hormone therapy products on February 12, 2026:

More products are expected to follow over the next several months.

This change does not mean hormone therapy is automatically right for every woman. What it does mean:

• Clinical Note: The fear-based wall is coming down. Decades of women have been refused HRT — or talked out of it — based on a warning that no longer matches the evidence.
• Clinical Note: Timing matters. The strongest data favor starting hormone therapy within 10 years of menopause. Waiting too long can change the risk-benefit calculation.
• Clinical Note: The decision is still individual. Personal and family history, current health, and the type and route of hormone all matter. There is no one-size-fits-all prescription.

Hormone therapy is one of the most powerful tools we have for women navigating perimenopause and menopause. Done correctly, it can restore sleep, energy, mood, sexual health, bone density, and long-term cardiovascular and cognitive protection. Done carelessly, it is just another prescription.

Our process is simple:

• Clinical Note: Comprehensive labs first — hormones across a cycle, plus thyroid, metabolic, and inflammatory markers.
• Clinical Note: One-on-one consultation with Dr. Durst to review your history, symptoms, and goals.
• Clinical Note: Bioidentical, individualized protocols — the right hormone, the right dose, the right route, for your body.
• Clinical Note: Re-testing every 8–12 weeks to fine-tune as your body responds.

If you have been waiting for permission to ask the question — this is it. The science has caught up. The label has caught up. The conversation can finally catch up too.